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Abstract
Background: MicroRNAs (miRNAs) are involved in the post-transcriptional regulation of genes. The objective of this
study was to investigate whether select urinary cell-free microRNA’s may serve as biomarkers in children with active lupus
nephritis (LN) and to assess their relationship to the recently identified combinatorial urine biomarkers, a.k.a. the LN-Panel
(neutrophil gelatinase associated lipocalin, monocyte chemotactic protein 1, transferrin, and beta-trace protein).
Methods: miRNAs (125a, 127, 146a, 150 and 155) were measured using real-time polymerase chain reaction in the urine
pellet (PEL) and supernatant (SUP) in 14 patients with active LN, 10 patients with active extra-renal lupus, and 10 controls.
The concentrations of the LN-Panel biomarkers (neutrophil gelatinase associated lipocalin, monocyte chemotactic
protein-1, transferrin, beta-trace protein) was assayed. Traditional laboratory and clinical measures of LN and lupus
(complements, protein to creatinine ratio; Systemic Lupus Erythematosus Disease Activity Index) were also measured.
Results: All tested miRNAs in the SUP, but not the PEL, were associated with the LN-Panel biomarkers (0.3 < |r Pearson| <
0.73; p < 0.05), miRNA125a, miRNA127,miRNA146a also with C3 and dsDNA antibody levels (|r Pearson| > 0.24; p < 0.05),
and miRNA146a with the renal domain of the SLEDAI (|r Pearson| = 0.32; p < 0.05). Mean miRNA levels of patients with
active LN did not statistically (P > 0.05) differ from those of SLE patients without LN or controls.
Conclusion: Levels of cell-free miR-125a, miR-150, and miR-155 in the urine supernatant are associated with the
expression of LN-Panel biomarkers and some LN measures. These miRNA’s may complement, but are unlikely
superior to the LN-Panel for estimating concurrent LN activity.
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Background
Lupus nephritis (LN) continues to result in a significant
morbidity and mortality [1, 2]. Current laboratory and
clinical measures of kidney involvement with systemic
lupus erythematosus (SLE) have been found unsuited to
monitor the course of LN accurately, making effective
LN therapy virtually impossible [3]. Therefore, there is
active ongoing research to identify improved measures
of LN activity which led to the discovery of several
combinatorial urinary protein biomarkers a.k.a. the LN-
Panel, consisting of neutrophil gelatinase associated lipoca-
lin (NGAL), monocyte chemotactic protein 1 (MCP-1),
transferrin (Tf), and beta trace protein (BTP; a.k.a lipocalin-
like prostaglandin synthase). Earlier studies suggest that the
LN-Panel can be used to diagnose active LN, anticipate LN
flares [4–6].
MicroRNAs (miRNAs), small non-coding RNAs about
20 nucleotides in length, are involved in the gene
expression at the post-transcriptional level [7]. MiRNAs
regulate an estimated 30 % of the human protein-coding
genome, including the expression of genes involved in
inflammation. Because miRNAs are characterized by
high stability in tissues and body fluids and protected
from endogenous RNAses, they are attractive candidate
biomarkers. Prior studies showed that there is differential
expression of miRNAs in the various renal compartments,
enabling discrimination of glomerular from tubulointersti-
tial inflammatory changes [8]. In this setting prior reports
suggested that especially miRNA’s 125a, 127, 146a, 150
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and 155 may be differentially expressed with inflammatory
kidney diseases, SLE or LN [9–11].
The objective of this pilot study was to explore the
potential of select cell-free miRNAs (125a, 127, 146a,
150 and 155) when measured in urine to serve as LN
biomarkers.
Methods
With the approval of the institutional review board and
after all the necessary consents and assents were obtained,
we studied patients diagnosed with SLE prior to age 18 years
[12] and a control with juvenile idiopathic arthritis (JIA) or
fibromyalgia in this prospective cohort study. While SLE
patients were studied every 6 months for up to three visits,
controls were asked to participate in only one study visit.
At enrollment all SLE patient needed to have either active
LN (LN-group) or active extra-renal SLE (SLE-group) as
measured by the SLE Disease Activity Index (SLEDAI;
score range of 0–105) [13]. Active LN was defined as a
renal SLEDAI domain score of ≥ 8 in patients with biopsy-
diagnosed LN (LN-Group), while active extra-renal SLE
was defined presence of a SLEDAI score ≥ 8, excluding the
renal domain items (proteinuria, hematuria, pyuria, cellular
urine casts). Additionally, for including in the SLE-group,
patients had to lack a history of LN and have minimum
disease duration of two year.
LN and SLE measures
At each study visit of SLE patients the SLEDAI was
completed. The renal domain scores served as a clinical
measure of LN activity (SLE-renal; score range 0–16)
and the remaining items were used to calculate an extra-
renal SLE activity score (SLEDAI-extrarenal; score range
0–89). We also measured the renal domain score of the
BILAG index as previously reported (BILAG-renal,
range 0–12) [14]. We also recorded complement C3 and
C4 levels, anti-dsDNA antibodies titer, amount of pro-
teinuria as estimated by the protein to creatinine (P/C)
ratio in a random urine sample, serum creatinine, and
the glomerular filtration rate (GFR) as estimated by the
modified Schwartz formula [15].
Laboratory assays for miRNA measurement and the
LN-Panel
miRNA determination
A single dose of urine preservative (Norgen Biotek,
Ontario, Canada) was added to each urine sample that
was intended for miRNA measurement prior to centrifu-
gation at 4000 g for 20 min to pellet the cells. We then
separated the urine sample to urine supernatant (SUP)
and urine pellet (PEL). Then the urine PEL and SUP
samples were frozen within 2 h of urine collection and
stored at −80 °C until the time of batch.
Five candidate miRNAs (125a, 127, 146a, 150 and 155 )
were selected based upon their proposed involvement in
the pathogenesis of lupus and kidney disease [10]. The
mirRNeasy Mini Kit (Qiagen, Valencia, CA) was used for
miRNA isolation from both the SUP and the PEL. As a
spike-in control, 5 μl of C. elegans-miR-39 were added to
each 5 ml aliquot of SUP and PEL. This was followed by
miRNA concentration measurements, using TaqMan miR
Real time PCR technology (Life technologies, Carlsbad,
CA). Till date, no reliable or validated endogenous control
miRNA has been established to normalize for the miRNA
content. We have used RNU48 as the housekeeping
miRNA to severe as reference standard. The data were
analyzed using the ΔΔCT method [16]. The miRNA levels
and the analysis shown are unadjusted to the urine
creatinine as adjusted analysis was the same.
LN-Panel biomarkers
We measured urinary concentrations of Tf and BTP by
immunonephelometry (Dade Behring Prospect, Marburg,
Germany). Intra and inter-assay coefficients of variation
(CV) of this assay were 3.4 % and 2.5 % for Tf and 2.3 %
and 6.5 % for BTP. Urine concentrations of MCP-1 were
measured by enzyme-linked immunosorbent assay (ELISA)
(Human MCP-1, R&D Systems, Minneapolis, MN, USA).
The respective intra-assay and inter-assay CV was 5.0 %
and 5.1 %. NGAL levels were quantified by ELISA (Kit 036;
AntibodyShop, Grusbakken, Denmark). Intra and inter-
assay CV of NGAL were 5.0 % and 5.1 %. Urine creatinine
measurements were made using a modified Jaffe reaction,
and microalbumin (MALB) was measured by immunotur-
bidimetry, both on a Dimension Xp and plus HM Clinical
Analyzer (Siemens, Munich, Germany). Coefficients of vari-
ability for the creatinine measurements were 2.4 % (intra)
and 4.2 % (total), and 2.9 % (intra) and 5.9 % (inter) for
MALB. TGF-β [CV inter/intra: 2.6 %/8.3 %] was measured
by ELISA (R&D Systems, Minneapolis, MN) after acid acti-
vation. Briefly, 20 μL of 1 N HCl was added to 100 μL of
urine sample, mixed by inversion and incubated at room
temperature for 10 min. Next, the acidified sample was
neutralized by adding 20 μL of 1.2 N NaOH/0.5 M HEPES,
then the assay was immediately run per manufacturer’s
instructions [CV inter/intra: 2.0 %/7.8 %].
All the urine biomarkers were normalized to urine
creatinine (in mg/mL). Laboratory personnel measur-
ing the urinary biomarkers were blinded to the clinical
information.
Statistical analysis
Urine levels of the LN-Panel biomarkers and the miRNAs
were considered primary measures in this study. They
were log-transformed in order to fit major assumptions of
parametric statistical models in analyses. For each miRNA
measure, its change over time was assessed using a
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mixed-effect model, adjusting for controlling covari-
ates, mainly the demographics. Other numerical vari-
ables were summarized by geometric mean ± SE
(standard error) values, and binary or categorical vari-
ables were summarized with frequency values (in %).
Groups of patients were assessed for statistically
significant differences using analysis of variance
(ANOVA). Associations between miRNA measures,
LN-Panel markers and other LN measures (SLEDAI,
complement levels, GFR, serum creatinine) were
assessed using Pearson’s correlation coefficients (r)
which can be interpreted as follows: between 0.2 and
0.39 is considered to be weak, 0.4 and 0.59 is consid-
ered moderate, 0.6 and 0.79 is strong, and 0.8 to 1.00
is a very strong correlation [17]. Excel XP (Microsoft,
Redmond, WA) and SAS 9.4 (SAS Institute, Cary, NC)
programs were used for analysis. Two-sided P values
less than 0.05 were considered significant.
Results
Characteristics of patients
The demographic information of the participants is sum-
marized in Table 1. There were 39 visits (baseline and
follow up visits) for the LN-group and 29 visits for the
SLE-group available for analysis. Majority of the LN pa-
tients had Class 4 (50 %) followed by Class 2 (28.6 %) as
per the International Society of Nephrology/Renal Path-
ology Society Classification for LN [18]. Controls with
JIA were treated with non-steroidal anti-inflammatory
medications (n = 2), methotrexate (MTX, n = 2) or eta-
nercept plus MTX (n = 1). None of the fibromyalgia pa-
tients was treated with anti-inflammatory medications.
Levels of candidate miRNAs
The mean urine concentrations of the miRNAs consid-
ered were statistically significantly higher in the PEL
than the SUP in all groups, including controls (p < 0.05).
However, as is summarized in Table 2, there were no sig-
nificant (P > 0.05) differences in any of the miRNA con-
centrations between the SLE-group and the LN-group,
or controls, irrespective of whether considering the
supernatant or the pellet. There was merely a trend to-
wards higher levels of miR-127 in the SUP of the SLE-
group compared to the LN-group. Notably, miRNA
levels lacked association with patient age, sex and race
(p > 0.05).
Association of candidate miRNAs with other LN measures
When measured in the PEL all of the miRNA had
weaker association to all of the LN and SLE measures
than miRNAs measured in the SUP. Table 3 summarizes
associations between miRNA levels in the SUP with SLE
and LN outcomes (Table 3). All of the LN-Panel bio-
markers were positively associated with SUP values of
miR125a and miR150 (0.4 < r ≤ 0.73; P < 0.05), while
miRNA127 and miRNA155 lacked association with
NGAL but still were weakly to moderately associated
with the other LN-Panel biomarkers (TF, BTP, MCP-1).
Besides miRNA127, all of the other miRNA when
measured in the SUP were associated with LN activity
(SLEDAI-renal; BILAG-renal), but correlations where
generally weaker than those of the LN-Panel biomarkers
(Table 3). Notable neither SUP miRNA levels nor the
LN-Panel biomarkers were related to SLEDAI-extrarenal
scores.
MiRNA levels and the course of LN
When examining miRNA levels over the course of LN
activity (renal-SLEDAI), only miR-146a in the SUP
showed a trend towards lower levels with worsening of
LN activity, and a trend towards higher levels with im-
proving LN activity (both P > 0.05). None of the other
miRNAs (miR125a, miR 127, miR 150, miR 155) was
found to have a consistent trend with the course of
activity.
Discussion
We found closer relationships between the levels of cell-
free miRNAs when measured in the urine supernatant
than the pellet with the presence of LN. Notably, the
urine concentrations of previously described protein bio-
markers a.k.a. the LN-Panel were more closely related to
the clinical presentation of LN than the cell-free miRNA
biomarkers considered in this pilot study.
Though the miRNAs 125a, 127, 146a, 150 and 155 are
produced by various kidney cells and free miRNA may
stem from circulation or urine, we failed to document
strong association with these miRNAs in the pellet with
either the extra-renal SLEDAI, renal –SLEDAI or the
traditional laboratory measures.
A potential explanation for observing some relation-
ships of miRNA’s with LN activity in the supernatant,
but not the pellet is that these detected miRNA in the
pellet may not reflect miRNA from the kidney, but ra-
ther from cells of the external urinary canal. For that
reason, we advocate that measurement of miRNA’s in
the urine should be done from supernatant and not the
pellet. We found urine miR-127 to be higher in the LN
group compared to the SLE group. Although this differ-
ence was not statistically significant, our findings were
similar to Dai R et al. who reported miR-127 to be up-
regulated in the splenocytes of Lpr mice [19]. More
studies are still needed to fully understand the signifi-
cance of miR-127 in LN.
Bench studies showed that the select miRNA have cru-
cial roles in regulating the immune response in the
pathogenesis of LN, either negatively like miR-146a and
155 or positively like miR-150 [10, 20]. When examining
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these miRNAs for their potential to serve as clinical bio-
markers in the urine, our cross-sectional and longitu-
dinal data indicate that only miR-146a had a weak
association with the renal–SLEDAI and changed with
the course of LN activity. This is in line with some pre-
vious studies [20, 21]. However, none of the other
miRNA measured were associated with clinical or la-
boratory measures of LN activity.
We have shown that the levels of miR125a, miR150 and
miR155 had associations with the levels of the LN-panel
biomarkers namely BTP, MCP-1 and Tf. These protein
biomarkers have been proven to be accurate biomarkers
of LN activity in previous studies [6, 22]. Possible hypoth-
eses to the association that we see between select miRNA’s
and the LN-Panel that these three miRNA’s may have an
important role in regulating the LN –Panel protein bio-
markers or indeed associated with LN activity, but due
low subject number , no significant association was found.
Our results indicate that these selected cell-free miRNAs
are unlikely superior to the LN-Panel as clinical bio-
markers for LN activity, and may be inferior based on per-
formance of the LN-Panel of having stronger associations
with the LN activity compared to the selected miRNA’s.
Also extracting the miRNAs from the urine compared
to the LN-Panel markers, are time consuming and assays
have not yet been standardized.
Some limitations of this study are there could be some
racial or gender differences that has been previously
reported, but we were not able to find them possibly due
to low subjects included [23]. Also our study examined
the role of only five miRNA’s and the values of other
miRNAs at large to serve as biomarkers for LN cannot
be fully excluded. Nonetheless, our study is still valuable
as we tested five highly relevant miRNAs reported for
LN. For future studies on miRNA as biomarkers, the use
of the high-throughput capacity technology offered by
arrays will be an excellent approach option, since hundreds
of miRNAs can be studied simultaneously. Another
Table 1 Demographics and clinical information
Features n of N (%) Mean (SD)
Lupus patients Controls Lupus Nephritis (LN),n, age (years) 14 18.33 ± 3.77
SLE without LN,n, age (years) 10 17.40 ± 2.59
Fibromyalgia 5
Juvenile Idiopathic Arthritis 5
Females 19 (79.1 %)
Race Black 13 (54.1 %)
White 8 (33.4 %)
Other° 3 (12.5 %)
Medications (SLE patients) Oral prednisone (mg/day) 24 (100 %) 26.1 (18.4)
Mycophenolate mofetil 10 (41.7 %)
Azathioprine 1 (4.1 %)
Cyclophosphamide 10 (41.7 %)
Diuretics 4 (16.6 %)
Angiotensin system blocking drug 12 (50 %)
LN Status (n = 14) GFR£ < 60 ml/min/m2 3 (21.4 %)
Protein:creatinine ratio > 0.5 11 (78.6 %)
Renal SLEDAI* score 5.6 (6.19)
Renal BILAG score 4.8 (4.54)
Class 2 4 (28.6 %)
ISN/RPS¶ Class 3 2 (14.3 %)
Class 4 7 (50 %)
Class 5 1 (7.1 %)
SLE Status (n = 24) Complement C3 low 9 (37.5 %)
Complement C4 low 16 (66.7 %)
Presence of anti-dsDNA antibodies 18 (75 %)
*Systemic Lupus Erythematosus Disease Activity Index, range 0–105; 0 – inactive LN
¶International Society for Nephrology Renal Pathology Society Class; there was no biopsy consistent with Class I or VI; °Other: includes Asians, Mixed race,
Native Indian
£GFR as estimated by the modified Schwartz formula
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Table 3 Associations of MiRNA and LN-Panel levels in the urine supernatant vs. traditional measuresa
Variablesb miR125a miR127 miR146a miR150 miR155 Tf BTP NGAL MCP-1
LN-Panel
Transferrin (Tf) 0.44 −0.24 - 0.65 0.54 1.0 - 0.42 0.27
BTP 0.73 −0.24 −0.37 0.68 0.35 - 1.0 0.43 0.21
NGAL 0.48 - −0.27 0.39 - - - 1.0 0.58
MCP-1 0.44 0.34 - 0.45 0.68 - - - 1.0
WBC (k/mcL) 0.23 - - 0.40 - 0.30 0.25 - 0.37
Hemoglobin (mg/dL) - - - - - −0.21 0.42 - -
Platelets count (k/mcL) −0.39 −0.24 - - - - 0.25 −0.27 −0.21
ESR (mm/h) - 0.24 - - - - 0.25 - 0.36
Anti-dsDNA titer - −0.31 −0.28 - −0.27 - 0.5 0.36
C3 level (mg/dL) −0.32 - 0.24 – −0.36 0.23 −0.43 −0.41 −0.2
C4 level (mg/dL) - - - - −0.29 - −0.26 −0.31 −0.21
Urine P/C ratio - - - 0.38 0.36 - - - -
GFR - - - −0.21
Renal - SLEDAId - - −0.32 - - 0.46 0.30 0.53 0.49
Renal BILAGe 0.29 - 0.29 0.27 0.20 0.46 0.26 0.48 0.31
Extrarenal SLEDAIc - - - - - - - - -
aOnly statistically significant associations with r values ≥ 0.20 are shown; “-“means, no statistically significant correlation was found (p > 0.05)
bValues are Pearson correlation coefficients of log-transformed urine concentrations the miRNAs listed withmiRmicro RNA, BTP beta trace protein, NGAL neutrophil gelatinase
associated lipocalin, MCP monocyte chemotactic protein 1, WBC white blood count, DSDNA anti-double stranded DNA titer, GFR glomerular filtration rate, P/C
protein to creatinine
cSLEDAI, Systemic Lupus Erythematosus Disease Activity Index, range 0–105; 0 inactive LN
dRenal-SLEDAI, renal domain of the Systemic Lupus Erythematosus Disease Activity Index
eRenal-BILAG, renal domain of the British Isles Lupus Activity Group Index
Table 2 Mean levels of the urinary miRNA’s in the supernatant and pellet in different groups at visit 1
Mean ± SEa P valueb
Controlsc (n = 10) SLE Group (n = 10) LN Group (n = 14)
Urine Supernatant
miR125a 5.83 ± 0.59 5.67 ± 0.53 6.66 ± 0.48 NS
miR127 6.65 ± 0.60 5.24 ± 0.54 5.26 ± 0.51 NS
miR146a 7.98 ± 0.93 7.61 ± 0.84 7.15 ± 0.76 NS
miR150 4.08 ± 0.73 4.08 ± 0.65 4.88 ± 0.62 NS
miR155 4.72 ± 0.64 4.03 ± 0.58 5.23 ± 0.53 NS
Urine Pellet
miR125a 9.45 ± 0.67 9.89 ± 0.60 10.21 ± 0.55 NS
miR127 8.87 ± 0.69 9.10 ± 0.62 8.59 ± 0.56 NS
miR146a 11.02 ± 0.52 10.74 ± 0.44 10.77 ± 0.40 NS
miR150 9.14 ± 0.62 9.34 ± 0.55 9.89 ± 0.53 NS
miR155 9.20 ± 0.62 9.10 ± 0.56 10.01 ± 0.51 NS
Values of miRNA’s are relative expression normalized to RNU48
miR micro RNA, JIA Juvenile Idiopathic Arthritis, LN Lupus Nephritis
aSE, standard Error
bP-values based on a t- test comparing means of all different groups , NS, not significant with p-value >0.05
cControls include fibromyalgia and the Juvenile idiopathic arthritis patients together and their values were almost identical
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limitation is till date, there has been no reliable or validated
endogenous control miRNA established to normalize for
the miRNA content in the urine. We used RNU48, as it has
been found to be a suitable housekeeping miRNAs in
urothelial and endometrial carcinomas and most likely it
will be suitable in the urine as well [24, 25] .
Our miRNA levels in the SUP and the PEL were gener-
ally very low compared to those usually found in the
blood. To be able to isolate larger amount of miRNA’s in
the urine we conducted a small pilot study (n = 7), using
similar patients, but instead of extracting free floating total
RNA from urine, we extracted them from exosomes by
differntial centrifugation of the urine . Exosomes are small
membrane vesicles with a size of 30–120 nm that are
released by different cell types. Exosomes can be isolated
from various body fluids. Lin-Li Lv et al. found that the
detection of miRNA from the exosomes were stable and
reproducible [26]. In line with this report, our pilot data
support that harvesting miRNA from urine exosomes
yields considerable higher amounts of miRNA than the
cell-free urine, and by doing so we may be able to detect
better and more valid associations.
Conclusions
Translational research on miRNA in LN is still in its
infancy. Our study in testing these five urinary cell-
free miRNA’s (125a, 127, 146a, 150 and 155) to serve
as biomarkers in LN appears less promising despite the
proven relationship of these miRNA’s to the pathogenesis
of SLE. Still further studies are needed and necessary to
include a more differentially regulated miRNA in patients
with LN and to examine their correlation in the urine.
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